

---

---

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION**  
Washington, D.C. 20549

---

**FORM S-8  
REGISTRATION STATEMENT**  
*UNDER  
THE SECURITIES ACT OF 1933*

---

**HEMAB THERAPEUTICS HOLDINGS, INC.**

(Exact Name of Registrant as Specified in Its Charter)

---

**Delaware**  
(State or Other Jurisdiction of  
Incorporation or Organization)

**101 Main Street, Suite 1220  
Cambridge, MA**  
(Address of Principal Executive Offices)

**41-4241952**  
(I.R.S. Employer  
Identification No.)

**02142**  
(Zip Code)

**Individual Warrant Agreements  
2026 Equity Incentive Plan  
2026 Employee Stock Purchase Plan**  
(Full Title of the Plan)

**Benny Sørensen**  
**President and Chief Executive Officer**  
**101 Main Street, Suite 1220  
Cambridge, MA 02142**  
(Name and Address of Agent For Service)

**(617) 553-3952**  
(Telephone Number, Including Area Code, of Agent For Service)

---

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of "large accelerated filer," "accelerated filer," "smaller reporting company," and "emerging growth company" in Rule 12b-2 of the Exchange Act.

Large accelerated filer   
Non-accelerated filer

Accelerated filer   
Smaller reporting company   
Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act.

---

---

**PART I**  
**INFORMATION REQUIRED IN THE SECTION 10(a) PROSPECTUS**

**Item 1. Plan Information.**

The information required by Item 1 is omitted from this registration statement and included in documents sent or given to participants in the plans covered by this registration statement pursuant to Rule 428(b)(1) of the Securities Act of 1933, as amended (the “Securities Act”), and the Note to Part I of Form S-8.

**Item 2. Registrant Information and Employee Plan Annual Information.**

The written statement required by Item 2 is omitted from this registration statement and included in documents sent or given to participants in the plans covered by this registration statement pursuant to Rule 428(b)(1) of the Securities Act and the Note to Part I of Form S-8.

**PART II**  
**INFORMATION REQUIRED IN THE REGISTRATION STATEMENT**

**Item 3. Incorporation of Documents by Reference.**

The registrant is subject to the informational and reporting requirements of Sections 13(a), 14, and 15(d) of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), and in accordance therewith files reports, proxy statements and other information with the Securities and Exchange Commission (the “Commission”). The following documents, which are on file with the Commission, are incorporated in this registration statement by reference:

(a) The registrant’s prospectus dated April 30, 2026, filed with the Commission pursuant to [Rule 424\(b\)](#) under the Securities Act, relating to the registration statement on Form S-1, as amended (File No. 333-294989), and all amendments to such registration statement; and

(b) the description of the registrant’s common stock contained in the registrant’s registration statement on [Form 8-A](#) (File No. 001-43250), filed with the Commission on April 27, 2026, together with any amendment thereto filed for the purpose of updating such description.

All documents subsequently filed by the registrant pursuant to Sections 13(a), 13(c), 14 and 15(d) of the Exchange Act, prior to the filing of a post-effective amendment which indicates that all securities offered hereby have been sold or which deregisters all securities then remaining unsold, shall be deemed to be incorporated by reference in this registration statement and to be part hereof from the date of the filing of such documents. Any statement contained in a document incorporated or deemed to be incorporated by reference herein shall be deemed to be modified or superseded for the purposes of this registration statement to the extent that a statement contained herein or in any other subsequently filed document which also is or is deemed to be incorporated by reference herein modifies or supersedes such statement. Any statement so modified or superseded shall not be deemed, except as so modified or superseded, to constitute a part of this registration statement.

**Item 4. Description of Securities.**

Not applicable.

**Item 5. Interests of Named Experts and Counsel.**

Not applicable.

**Item 6. Indemnification of Directors and Officers.**

The following summary is qualified in its entirety by reference to the complete Delaware General Corporation Law (“DGCL”) and the registrant’s restated certificate of incorporation (“Certificate of Incorporation”) and the registrant’s amended and restated bylaws, in each case that will be effective immediately prior to the completion of its initial public offering of common stock.

Section 102(b)(7) of the DGCL provides, generally, that a corporation may include in its certificate of incorporation a provision eliminating or limiting the personal liability of a director or officer to the corporation or its shareholders for monetary damages for breach of fiduciary duty as a director or officer, provided that such provision may not eliminate or limit the liability of (i) a director or officer for any breach of the director’s or officer’s duty of loyalty to the corporation or its shareholders, (ii) a director or officer for acts or omissions not in good faith or which involve intentional misconduct or a knowing violation of law, (iii) a director under section 174 of the DGCL, (iv) a director or officer for any transaction from which the director or officer derived an improper personal benefit or (v) an officer in any action by or in the right of the corporation. No such provision may eliminate or limit the liability of a director or officer for any act or omission occurring prior to the date when such provision became effective.

Section 145 of the DGCL provides, generally, that a corporation shall have the power to indemnify any person who was or is a party or is threatened to be made a party to any threatened, pending or completed action, suit or proceeding (except actions by or in the right of the corporation) by reason of the fact that such person is or was a director, officer, employee or agent of the corporation against all expenses, judgments, fines and amounts paid in settlement actually and reasonably incurred by such person in connection with such action, suit or proceeding if such person acted in good faith and in a manner such person reasonably believed to be in or not opposed to the best interests of the corporation and, with respect to any criminal action or proceeding, had no reasonable cause to believe his or her conduct was unlawful. A corporation may similarly indemnify such person for expenses actually and reasonably incurred by such person in connection with the defense or settlement of any action or suit by or in the right of the corporation, *provided* that such person acted in good faith and in a manner he or she reasonably believed to be in or not opposed to the best interests of the corporation, and, in the case of claims, issues and matters as to which such person shall have been adjudged liable to the corporation, *provided* that a court shall have determined, upon application, that, despite the adjudication of liability but in view of all of the circumstances of the case, such person is fairly and reasonably entitled to indemnity for such expenses which such court shall deem proper.

The Certificate of Incorporation provides that the registrant will indemnify each person who was or is a party or threatened to be made a party to any threatened, pending or completed action, suit or proceeding, whether civil, criminal, administrative or investigative (other than an action by or in the right of the registrant), by reason of the fact that he or she is or was, or has agreed to become, a director or officer of the registrant or, while a director or officer of the registrant, is or was serving, or has agreed to serve, at the request of the registrant as a director, officer, partner, employee or trustee of, or in a similar capacity with, another corporation, partnership, joint venture, trust or other enterprise (including any employment benefit plan) (all such persons being referred to as an “Indemnitee”), or by reason of any action alleged to have been taken or omitted by an Indemnitee in such capacity, against all expenses (including attorneys’ fees), liabilities, losses judgments, fines (including excise taxes and penalties arising under the Employee Retirement Income Security Act of 1974), and amounts paid in settlement actually

and reasonably incurred on or on behalf of the Indemnitee in connection with such action, suit or proceeding and any appeal therefrom, if such Indemnitee acted in good faith and in a manner he or she reasonably believed to be in, or not opposed to, the best interests of the registrant, and, with respect to any criminal action or proceeding, he or she had no reasonable cause to believe his or her conduct was unlawful.

The Certificate of Incorporation also provides that the registrant will indemnify any Indemnitee who was or is a party to or threatened to be made a party to any threatened, pending or completed action or suit by or in the right of the registrant to procure a judgment in the registrant's favor by reason of the fact that the Indemnitee is or was, or has agreed to become, a director or officer of the registrant or, while a director or officer of the registrant, is or was serving, or has agreed to serve, at the request of the registrant as a director, officer, partner, employee, or trustee of, or in a similar capacity with, another corporation, partnership, joint venture, trust, or other enterprise (including any employee benefit plan), or by reason of any action alleged to have been taken or omitted by he or she in such capacity, against all expenses (including attorneys' fees) and, to the extent permitted by law, amounts paid in settlement actually and reasonably incurred by or on behalf of the Indemnitee in connection with such action, suit or proceeding, and any appeal therefrom, if the Indemnitee acted in good faith and in a manner he or she reasonably believed to be in, or not opposed to, the best interests of the registrant, except that no indemnification shall be made in respect of any claim, issue or matter as to which such person shall have been adjudged to be liable to the registrant, unless, and only to the extent, that the Court of Chancery of Delaware or the court in which such action or suit was brought shall determine upon applications that, despite the adjudication of such liability but in view of all the circumstances of the case, he or she is fairly and reasonably entitled to indemnify for expenses (including attorney's fees) which the Court of Chancery of Delaware or such other court shall deem proper. Notwithstanding the foregoing, to the extent that any Indemnitee has been successful, on the merits or otherwise, he or she will be indemnified by the registrant against all expenses (including attorneys' fees) actually and reasonably incurred by him or her or on his or her behalf in connection therewith. If the registrant does not assume the defense, expenses must be advanced to an Indemnitee under certain circumstances.

In addition, the registrant has entered into indemnification agreements with all of the registrant's executive officers and directors. In general, these agreements provide that the registrant will indemnify the executive officer or director to the fullest extent permitted by law for claims arising in his or her capacity as an executive officer or director of the registrant or in connection with his or her service at the request of the registrant for another corporation or entity. The indemnification agreements also provide for procedures that will apply in the event that an executive officer or director makes a claim for indemnification and establish certain presumptions that are favorable to the executive officer or director.

The registrant maintains a general liability insurance policy that covers certain liabilities of the registrant's directors and officers arising out of claims based on acts or omissions in their capacities as directors or officers.

**Item 7. Exemption from Registration Claimed.**

Not applicable.

## Item 8. Exhibits.

The following exhibits are incorporated herein by reference:

<u>Number</u>	<u>Description</u>
4.1	<a href="#"><u>Amended and Restated Certificate of Incorporation of the registrant (incorporated by reference to Exhibit 3.1 to the registrant's Registration Statement on Form S-1 (File No. 333-294989) filed with the Securities and Exchange Commission on April 10, 2026)</u></a>
4.2	<a href="#"><u>Certificate of Amendment to the Amended and Restated Certificate of Incorporation of the registrant, effective April 24, 2026 (incorporated by reference to Exhibit 3.5 to Amendment No. 1 to the registrant's Registration Statement on Form S-1 (File No. 333-294989) filed with the Securities and Exchange Commission on April 27, 2026)</u></a>
4.3	<a href="#"><u>Amended and Restated By-Laws of the registrant (incorporated by reference to Exhibit 3.2 to the registrant's Registration Statement on Form S-1 (File No. 333-294989) filed with the Securities and Exchange Commission on April 10, 2026)</u></a>
4.4	<a href="#"><u>Form of Restated Certificate of Incorporation of the registrant (to be effective immediately prior to the completion of the registrant's initial public offering)(incorporated by reference to Exhibit 3.3 to Amendment No. 1 to the registrant's Registration Statement on Form S-1 (File No. 333-294989) filed with the Securities and Exchange Commission on April 27, 2026)</u></a>
4.5	<a href="#"><u>Form of Amended and Restated Bylaws of the registrant (to be effective immediately prior to the completion of the registrant's initial public offering)(incorporated by reference to Exhibit 3.4 to Amendment No. 1 to the registrant's Registration Statement on Form S-1 (File No. 333-294989) filed with the Securities and Exchange Commission on April 27, 2026)</u></a>
4.6	<a href="#"><u>Form of Warrant Agreement (incorporated by reference to Exhibit 4.2 to the registrant's Registration Statement on Form S-1 (File No. 333-294989) filed with the Securities and Exchange Commission on April 10, 2026)</u></a>
5.1*	<a href="#"><u>Opinion of Wilmer Cutler Pickering Hale and Dorr LLP, counsel to the registrant</u></a>
23.1*	<a href="#"><u>Consent of Wilmer Cutler Pickering Hale and Dorr LLP (included in Exhibit 5.1)</u></a>
23.2*	<a href="#"><u>Consent of EY Godkendt Revisionspartnerselskab, independent registered public accounting firm</u></a>
24.1*	<a href="#"><u>Power of attorney (included on the signature pages of this registration statement)</u></a>
99.1	<a href="#"><u>2026 Equity Incentive Plan (incorporated by reference to Exhibit 10.1 to Amendment No. 1 to the registrant's Registration Statement on Form S-1 (File No. 333-294989) filed with the Securities and Exchange Commission on April 27, 2026)</u></a>
99.2	<a href="#"><u>2026 Employee Stock Purchase Plan (incorporated by reference to Exhibit 10.3 to Amendment No. 1 to the registrant's Registration Statement on Form S-1 (File No. 333-294989) filed with the Securities and Exchange Commission on April 27, 2026)</u></a>
107*	<a href="#"><u>Filing Fee Table</u></a>

\* Filed herewith.

**Item 9. Undertakings.**

1. The undersigned registrant hereby undertakes:

(1) To file, during any period in which offers or sales are being made, a post-effective amendment to this registration statement:

(i) To include any prospectus required by Section 10(a)(3) of the Securities Act;

(ii) To reflect in the prospectus any facts or events arising after the effective date of the registration statement (or the most recent post-effective amendment thereof) which, individually or in the aggregate, represent a fundamental change in the information set forth in the registration statement. Notwithstanding the foregoing, any increase or decrease in volume of securities offered (if the total dollar value of securities offered would not exceed that which was registered) and any deviation from the low or high end of the estimated maximum offering range may be reflected in the form of prospectus filed with the Commission pursuant to Rule 424(b) if, in the aggregate, the changes in volume and price represent no more than 20% change in the maximum aggregate offering price set forth in the "Calculation of Filing Fee Tables" in the effective registration statement; and

(iii) To include any material information with respect to the plan of distribution not previously disclosed in the registration statement or any material change to such information in the registration statement;

*provided, however,* that paragraphs (1)(i) and (ii) do not apply if the information required to be included in a post-effective amendment by those paragraphs is contained in reports filed with or furnished to the Commission by the registrant pursuant to Section 13 or Section 15(d) of the Exchange Act that are incorporated by reference in the registration statement.

(2) That, for the purpose of determining any liability under the Securities Act, each such post-effective amendment shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial *bona fide* offering thereof.

(3) To remove from registration by means of a post-effective amendment any of the securities being registered which remain unsold at the termination of the offering.

2. The undersigned registrant hereby undertakes that, for purposes of determining any liability under the Securities Act, each filing of the registrant's annual report pursuant to Section 13(a) or Section 15(d) of the Exchange Act (and, where applicable, each filing of an employee benefit plan's annual report pursuant to Section 15(d) of the Exchange Act) that is incorporated by reference in the registration statement shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial *bona fide* offering thereof.

3. Insofar as indemnification for liabilities arising under the Securities Act may be permitted to directors, officers and controlling persons of the registrant pursuant to the foregoing provisions, or otherwise, the registrant has been advised that in the opinion of the Securities and Exchange Commission such indemnification is against public policy as expressed in the Securities Act and is, therefore, unenforceable. In the event that a claim for indemnification against such liabilities (other than the payment by the registrant of expenses incurred or paid by a director, officer or controlling person of the registrant in the successful defense of any action, suit or proceeding) is asserted by such director, officer or controlling person in connection with the securities being registered, the registrant will, unless in the opinion of its counsel the matter has been settled by controlling precedent, submit to a court of appropriate jurisdiction the question whether such indemnification by it is against public policy as expressed in the Securities Act and will be governed by the final adjudication of such issue.

## SIGNATURES

Pursuant to the requirements of the Securities Act of 1933, the registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this registration statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Cambridge, Commonwealth of Massachusetts, on this 1st day of May, 2026.

HEMAB THERAPEUTICS HOLDINGS, INC.

By: /s/ Benny Sørensen, M.D., Ph.D.

Benny Sørensen, M.D., Ph.D.  
President and Chief Executive Officer

## POWER OF ATTORNEY AND SIGNATURES

We, the undersigned officers and directors of Hemab Therapeutics Holdings, Inc., hereby severally constitute and appoint Benny Sørensen and Mads Behrndt, and each of them singly, our true and lawful attorneys with full power to them, and each of them singly, to sign for us and in our names in the capacities indicated below, the registration statement on Form S-8 filed herewith and any and all subsequent amendments to said registration statement, and generally to do all such things in our names and on our behalf in our capacities as officers and directors to enable Hemab Therapeutics Holdings, Inc. to comply with the provisions of the Securities Act of 1933, as amended, and all requirements of the Securities and Exchange Commission, hereby ratifying and confirming our signatures as they may be signed by our said attorneys, or any of them, to said registration statement and any and all amendments thereto.

Pursuant to the requirements of the Securities Act of 1933, this registration statement has been signed by the following persons in the capacities and on the dates indicated.

<u>Signature</u>	<u>Title</u>	<u>Date</u>
<u>/s/ Benny Sørensen, M.D., Ph.D.</u> Benny Sørensen, M.D., Ph.D.	President and Chief Executive Officer, Director (Principal executive officer)	May 1, 2026
<u>/s/ Mads Behrndt, M.Sc.</u> Mads Behrndt, M.Sc.	Chief Financial Officer (Principal financial and accounting officer)	May 1, 2026
<u>/s/ John Maraganore, Ph.D.</u> John Maraganore, Ph.D.	Chair of the Board	May 1, 2026
<u>/s/ Linda Catharina Bain</u> Linda Catharina Bain	Director	May 1, 2026
<u>/s/ Laura Tadvalkar, Ph.D.</u> Laura Tadvalkar, Ph.D.	Director	May 1, 2026
<u>/s/ Akshay Vaishnaw, M.D., Ph.D.</u> Akshay Vaishnaw, M.D., Ph.D.	Director	May 1, 2026

May 1, 2026

Hemab Therapeutics Holdings, Inc.  
101 Main Street, Suite 1220  
Cambridge, MA 02142

Re: Warrant Agreements  
2026 Equity Incentive Plan  
2026 Employee Stock Purchase Plan

Ladies and Gentlemen:

We have assisted in the preparation of a Registration Statement on Form S-8 (the "Registration Statement") to be filed with the Securities and Exchange Commission (the "Commission") under the Securities Act of 1933, as amended (the "Securities Act"), relating to an aggregate of 8,970,742 shares (the "Shares") of common stock, \$0.0001 par value per share ("Common Stock"), of Hemab Therapeutics Holdings, Inc., a Delaware corporation (the "Company"), consisting of (i) an aggregate of 4,362,116 shares of Common Stock issuable upon the exercise of warrants to acquire Common Stock that were outstanding immediately prior to the effectiveness of the Company's Registration Statement on Form S-1 (File No. 333-294989) (the "Warrants"), (ii) an aggregate of 4,180,000 shares of Common Stock issuable under the Company's 2026 Equity Incentive Plan (the "2026 Plan") and (iii) an aggregate of 418,000 shares of Common Stock issuable under the Company's 2026 Employee Stock Purchase Plan (the "2026 ESPP" and, together with the "2026 Plan", the "Plans").

We have examined the Certificate of Incorporation and the Bylaws of the Company, each as amended and/or restated to date, and originals, or copies certified to our satisfaction, of all pertinent records of the meetings of the board of directors and stockholders of the Company, the Registration Statement, the form of Warrants, the Plans and such other documents relating to the Company as we have deemed material for the purposes of this opinion.

In our examination of the foregoing documents, we have assumed the genuineness of all signatures, the authenticity of all documents submitted to us as originals, the conformity to original documents of all documents submitted to us as certified, photostatic or other copies, the authenticity of the originals of any such documents and the legal competence of all signatories to such documents.

We assume that the appropriate action will be taken, prior to the offer and sale of the Shares in accordance with the Warrants or the Plans, as applicable, to register and qualify the Shares for sale under all applicable state securities or "blue sky" laws.

We express no opinion herein as to the laws of any state or jurisdiction other than the General Corporation Law of the State of Delaware.

It is understood that this opinion is to be used only in connection with the offer and sale of the Shares while the Registration Statement is in effect.

Please note that we are opining only as to the matters expressly set forth herein, and no opinion should be inferred as to any other matters.

Based on the foregoing, we are of the opinion that the Shares have been duly authorized for issuance and, when the Shares are issued and paid for in accordance with the terms and conditions of the Warrants or the Plans, as applicable, including the payment of the exercise price therefor, the Shares will be validly issued, fully paid and nonassessable.

We hereby consent to the filing of this opinion with the Commission in connection with the Registration Statement in accordance with the requirements of Item 601(b)(5) of Regulation S-K under the Securities Act. In giving such consent, we do not hereby admit that we are in the category of persons whose consent is required under Section 7 of the Securities Act or the rules and regulations of the Commission.

Very truly yours,

/s/ Wilmer Cutler Pickering Hale and Dorr LLP

WILMER CUTLER PICKERING HALE AND DORR LLP

**Consent of Independent Registered Public Accounting Firm**

We consent to the incorporation by reference in the Registration Statement (Form S-8) pertaining to the 2026 Equity Incentive Plan and the 2026 Employee Stock Purchase Plan of Hemab Therapeutics Holdings, Inc. of our report dated February 27, 2026 (except for Note 16(a), as to which the date is April 10, 2026, and Note 16(b) and (c), as to which the date is April 27, 2026), with respect to the consolidated financial statements of Hemab ApS included in the registration statement on Form S-1 (File No. 333-294989), as amended, filed with the Securities and Exchange Commission.

/s/ EY Godkendt Revisionspartnerselskab

Copenhagen, Denmark  
May 1, 2026

# Calculation of Filing Fee Tables

## S-8

### Hemab Therapeutics Holdings, Inc.

Table 1: Newly Registered Securities

Security Type	Security Class Title	Fee Calculation Rule	Amount Registered	Proposed Maximum Offering Price Per Unit	Maximum Aggregate Offering Price	Fee Rate	Amount of Registration Fee
1 Equity	Common Stock, \$0.0001 par value per share	Other	4,291,100	\$ 31.78	136,371,158.00	0.0001381	\$ 18,832.86
2 Equity	Common Stock, \$0.0001 par value per share	Other	306,900	\$ 18.00	\$ 5,524,200.00	0.0001381	\$ 762.90
3 Equity	Common Stock, \$0.0001 par value per share	Other	4,362,116	\$ 5.84	25,474,757.44	0.0001381	\$ 3,518.07
Total Offering Amounts:					\$		\$ 23,113.83
					167,370,115.44		
Total Fee Offsets:							\$ 0.00
Net Fee Due:							\$ 23,113.83

#### Offering Note

<sup>1</sup> (A) In accordance with Rule 416 under the Securities Act of 1933, as amended (the "Securities Act"), this registration statement shall be deemed to cover any additional securities that may from time to time be offered or issued to prevent dilution resulting from stock splits, stock dividends or similar transactions. (B) Consists of (i) 3,873,100 shares issuable under the registrant's 2026 Equity Incentive Plan (the "2026 Plan") and (ii) 418,000 shares issuable under the registrant's 2026 Employee Stock Purchase Plan. (C) Estimated solely for the purpose of calculating the registration fee pursuant to Rules 457(c) and 457(h) of the Securities Act. The proposed maximum offering price per share is based on \$31.78 per share, which is the average of the high and low sales prices of the registrant's common stock as reported on the Nasdaq Global Select Market on May 1, 2026.

<sup>2</sup> (A) See Note 1(A). (B) Consists of 306,900 shares issuable upon the exercise of stock options to acquire common stock granted under the 2026 Plan (the "Outstanding Options"). (C) Estimated solely for the purpose of calculating the registration fee pursuant to Rule 457(h) of the Securities Act. The proposed maximum offering price per share is based on \$18.00 per share, which is the exercise price of the Outstanding Options.

<sup>3</sup> (A) See Note 1(A). (B) Consists of 4,362,116 shares issuable upon the exercise of warrants to acquire common stock that were outstanding immediately prior to the effectiveness of the registrant's Registration Statement on Form S-1 (File No. 333-294989), as amended (the "Outstanding Warrants"). (C) Estimated solely for the purpose of calculating the registration fee pursuant to Rule 457(h) of the Securities Act. The proposed maximum offering price per share is based on \$5.84 per share, which is the weighted average exercise price of the Outstanding Warrants.

Table 2: Fee Offset Claims and Sources

Not Applicable

Registrant or Filer Name	Form or Filing Type	File Number	Initial Filing Date	Filing Date	Fee Offset Claimed	Security Type Associated with Fee	Security Title Associated with Fee	Unsold Securities Associated with Fee	Unsold Aggregate Offering Amount	Fee Paid with Fee
--------------------------	---------------------	-------------	---------------------	-------------	--------------------	-----------------------------------	------------------------------------	---------------------------------------	----------------------------------	-------------------

